SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosisdiabetic hindlimb ischemiaempagliflozinferroptosisrevascularizationtherapeutic angiogenesisGliflozins are known as SGLT2 inhibitors, which are used to treat diabetic patients by inhibiting glucose ...
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice Article Open access 17 March 2023 SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis Article Open access 02 September 2024 ...
inhibitor. Therefore, the direct cardiovascular protective effects are unlikely achieved through SGLT2 suppression. The greater possibility is that the unexpected off-target actions of various SGLT2i directly or indirectly impact on the cardiomyocyte as a “class effect” considered that they are structu...
The SGLT2 levels were determined in normal colon CCD 841 CoN and, HCT 116, HT-29, SW480 and LoVo colorectal cancer (CRC) cell lines by quantitative real-time PCR and western blot. The effect of iSGLT2 canagliflozin on cell proliferation was examined using CCK-8, as its role on CRC ce...
And sotagliflozin is dual SGLT1/2 inhibitor. Therefore, the direct cardiovascular protective effects are unlikely achieved through SGLT2 suppression. The greater possibility is that the unexpected off-target actions of various SGLT2i directly or indirectly impact on the cardiomyocyte as a “class ...
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA-REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits of EMPA in non-diabetic...
SGLT‐2 inhibitors have potential anti‐proliferative roles due to several underlying pathophysiological mechanisms, such as inhibition of ATP production, activation of AMPK signalling, induction of apoptosis and ferroptosis, inhibition of glutamate dehydrogenase activity and inhibition of DNA and ...
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approve